LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

17.81 -2.2

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.71

Максимум

18.34

Ключови измерители
By Trading Economics
Приходи	4.8M -36M
Продажби	6.1M 116M
Марж на печалбата	-30.977
Служители	1,869
EBITDA	24M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+199.45% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-903M 2.1B
Предишно отваряне	20.01
Предишно затваряне	17.81

Настроения в новините

By Acuity

31%

69%

107 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.12.2025 г., 23:58 ч. UTC

Придобивния, сливания и поглъщания

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11.12.2025 г., 23:56 ч. UTC

Печалби

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11.12.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Печалби

Costco Same-Store Sales, Membership Fees Rose in 1Q

11.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.12.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11.12.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11.12.2025 г., 23:31 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:35 ч. UTC

Печалби

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11.12.2025 г., 22:30 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11.12.2025 г., 22:05 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11.12.2025 г., 21:38 ч. UTC

Печалби

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Пазарно говорене

Broadcom Sees AI Revenue Doubling -- Market Talk

11.12.2025 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Dexus Aiming for Long-Term Holding of A$50M in Fund

11.12.2025 г., 21:28 ч. UTC

Пазарно говорене

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus: Third Party Investors to Contribute Remainder

11.12.2025 г., 21:27 ч. UTC

Придобивния, сливания и поглъщания

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11.12.2025 г., 21:25 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

199.45% нагоре

12-месечна прогноза

Среден 54.74 USD 199.45%

Висок 74 USD

Нисък 25.7 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

107 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.